Official HUMIRA (adalimumab) Site
HS symptoms in women's armpit and breast

SIGNS & SYMPTOMS OF
HIDRADENITIS SUPPURATIVA (HS)

Not an actual HS patient. HUMIRA is the first & only FDA-approved treatment for moderate to severe hidradenitis suppuritiva

STAGES OF HS

Moderate to severe HS can be progressive and debilitating.2-5 The severity of HS may be determined by the Hurley staging system, a widely used classification.6

Hidradenitis suppurativa Hurley stage 1

STAGE I

Typically presents as abscess formation, single or multiple, without sinus tracts and scarring

Hurley Stages II and III studied
in PIONEER pivotal trials

Hidradenitis suppurativa  Hurley stage 2

STAGE II

Typically presents as recurrent abscesses with sinus tract formation and scarring; single or multiple widely separated lesions

Hidradenitis suppurativa  Hurley stage 3

STAGE III

Typically presents as diffuse or near-diffuse involvement with multiple interconnected sinus tracts and abscesses across entire area

Adapted with permission from Jemec, 2012.6

HS is a chronic, debilitating immune-mediated disease that manifests on the skin, occurring in many patients’ most sensitive areas.2,3,7 Typical signs and symptoms of moderate to severe HS lesions include7:

Multiple nodules and abscesses

Sinus tracts

Malodorous discharge

Inflammation in the dermis

Scarring, ulceration, and infection

PRESENTATION OF HS LESIONS IN
WOMEN AND MEN

Recurring lesions commonly affect these sensitive areas in women and men.3,8 Symptoms can start at any time between puberty and middle age—one study states the average age of onset is 21.5

Presentation of sensitive recurring HS lesions in women
Presentation of sensitive recurring HS lesions in men

“As you can imagine, this disease can make sitting uncomfortable when I have several large lesions around my inner thighs and buttocks.”

FIND A DERMATOLOGIST
FOR A REFERRAL

“The patient was [Hurley stage II/III and in need of some] relief from this condition.... While the family physician was not comfortable prescribing an injectable biologic medication, he offered the patient a referral to dermatology.”

PREVALENCE OF HS

HS is relatively rare. The prevalence of all forms of HS reported in published literature varies. It is estimated that the number of adults in the U.S. living with the moderate to severe form of HS is between 115,000 and 189,000.10

Females are more likely than males to develop HS, with a 3:1 ratio.11

But HS may be more common than you think, as it is often misdiagnosed, or goes undiagnosed for years when hidden by embarrassed patients.3,8 From an AbbVie conducted market research survey, patients with HS on average see 5 doctors over 8 years before they are properly diagnosed.12

RISK FACTORS TO CONSIDER

The development of HS depends on a combination of factors. However, it may be helpful to know that the data on patients with HS has some patterns to help you recognize this often overlooked disease.

GENETIC FACTORS: 30%-40% of patients with HS have at least one family member who has it as well13

HORMONAL FACTORS: A strong relationship exists between HS and sex hormones, as demonstrated by the onset after puberty, and lack of onset after menopause14

MECHANICAL FACTORS: Weak structural support at the junction of the sebaceous gland and the follicular duct likely predisposes to follicular rupture caused by local trauma14

OBESITY may exacerbate HS symptoms, with higher body mass index associated with increased disease severity15

SMOKING can promote follicular plugging, which may contribute to the pathogenesis of HS14

COMORBIDITIES such as Crohn's disease or spondyloarthropathy often may be present in patients with HS14

FIND A DERMATOLOGIST
FOR A REFERRAL

“The swelling, the discharge—I know this is an incurable disease, but is it wrong for me to hope for something that can help my lesions?”

Please Note

By clicking this link, you’ll be leaving hspartnership.com and going to a website not sponsored by AbbVie.

Is this what you would like to do?

You are about to enter a site that is for U.S. Healthcare Professionals Only.

By selecting “Yes” below, you certify that you are a Healthcare Professional and that you wish to proceed to the Healthcare Professionals Only section on the AbbVie Medical Information site. Products or treatments described on this site are available in the U.S. but may not be available in all other countries. I am a licensed Healthcare Professional and wish to proceed to the Healthcare Professionals Only AbbVie Medical Information Site.

Terms and Conditions

AbbVie is providing this service to help patients find dermatologists in their area who have experience with HUMIRA.

No fees have been received by or paid to dermatologists for inclusion in this specialist locator directory. Inclusion of a physician in this directory does not represent an endorsement by or a recommendation from AbbVie Inc., nor does it imply that the dermatologists on the list will determine if HUMIRA is right for you.

The selection of a physician is an important decision that should not be based solely on the inclusion in this dermatologist locator tool.

AbbVie Inc. is a maker and marketer of HUMIRA (adalimumab).